Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SGHT

Sight Sciences Inc

Dec 01 • 04:00PM ET

2.90

Dollar change -0.51
Percentage change -14.96	%

Healthcare • Medical Devices • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.28	Insider Own	42.92%	Shs Outstand	48.30M	Perf Week	-6.45%
Market Cap	141.38M	Forward P/E	-	EPS next Y	-1.15	Insider Trans	4.94%	Shs Float	27.00M	Perf Month	83.54%
Income	-61.76M	PEG	-	EPS next Q	-0.33	Inst Own	36.96%	Short Float / Ratio	3.59% / 2.02	Perf Quarter	-55.66%
Sales	82.85M	P/S	1.71	EPS this Y	30.55%	Inst Trans	-2.95%	Short Interest	0.97M	Perf Half Y	-61.44%
Book/sh	2.63	P/B	1.10	EPS next Y	8.20%	ROA	-30.74%	Target Price	2.58	Perf Year	-74.04%
Cash/sh	2.96	P/C	0.98	EPS next 5Y	-	ROE	-41.17%	52W Range	1.04 - 15.30	Perf YTD	-76.25%
Dividend	-	P/FCF	-	EPS past 5Y	-55.84%	ROI	-38.40%	52W High	-81.04%	Beta	2.65
Dividend %	-	Quick Ratio	11.47	Sales past 5Y	87.82%	Gross Margin	84.58%	52W Low	178.85%	ATR	0.34
Employees	250	Current Ratio	12.11	Sales Q/Q	7.13%	Oper. Margin	-76.31%	RSI (14)	52.34	Volatility	11.20% 13.62%
Optionable	Yes	Debt/Eq	0.27	EPS Q/Q	42.28%	Profit Margin	-74.55%	Rel Volume	1.14	Prev Close	3.41
Shortable	Yes	LT Debt/Eq	0.27	Earnings	Nov 07 AMC	Payout	-	Avg Volume	480.65K	Price	2.90
Recom	2.67	SMA20	22.38%	SMA50	0.00%	SMA200	-59.06%	Volume	547,102	Change	-14.96%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-12-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-12-23	Downgrade	Piper Sandler	Overweight → Neutral	$15 → $5.50
Sep-12-23	Downgrade	BofA Securities	Neutral → Underperform	$10 → $4.50
Aug-24-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$12 → $8.40
Jul-10-23	Downgrade	Citigroup	Buy → Neutral	$15 → $9
Jan-06-23	Upgrade	Stifel	Hold → Buy	$10 → $15
Oct-04-22	Initiated	Needham	Hold
Jul-26-22	Initiated	Stifel	Hold	$10
Feb-03-22	Initiated	William Blair	Outperform
Jan-07-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$36 → $27

Nov-13-23 03:40PM	5 Risky Stocks to Buy Immediately, According to AI (InvestorPlace)
Nov-12-23 09:40AM	Sight Sciences, Inc. (NASDAQ:SGHT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 04:05PM	Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023 (GlobeNewswire) +22.09%
Oct-26-23 05:30PM	Ekso Bionics (EKSO) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -64.27%
Oct-24-23 04:05PM	Sight Sciences to Report Third Quarter 2023 Financial Results on November 7, 2023 (GlobeNewswire)
04:05PM	Loading…
Oct-19-23 04:05PM	Sight Sciences to Host SAHARA 6 Month RCT Results Reception at the American Academy of Ophthalmology 2023 (GlobeNewswire) -6.63%
Oct-12-23 04:05PM	Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare to Restasis for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting (GlobeNewswire)
Oct-03-23 08:30AM	Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR Using OMNI Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma (GlobeNewswire) +5.93%
Sep-12-23 09:53AM	CVS upgraded, RTX downgraded: Wall Street's top analyst calls (The Fly) -49.62%
02:55AM	4 big analyst cuts: RTX pelted with 2 downgrades on word of $3B hit (Investing.com)
Sep-11-23 04:06PM	Sight Sciences Provides Revenue Guidance for the Third Quarter of 2023 and Updates Revenue Guidance for Full Year 2023 (GlobeNewswire) +6.03%
04:05PM	Sight Sciences Appoints Matt Link as Chief Commercial Officer (GlobeNewswire)
Aug-30-23 04:05PM	Sight Sciences to Present at the Upcoming Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-03-23 06:35PM	Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Sight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023 (GlobeNewswire)
09:55AM	Loading…
Jul-24-23 09:55AM	Wall Street Analysts Predict a 44.19% Upside in Sight Sciences, Inc. (SGHT): Here's What You Should Know (Zacks)
Jul-20-23 04:05PM	Sight Sciences to Report Second Quarter 2023 Financial Results on August 3, 2023 (GlobeNewswire)
08:30AM	Sight Sciences Announces Positive Results and Primary Endpoint Successfully Met in SAHARA, a Randomized Controlled Clinical Trial Comparing Interventional Eyelid Procedures Enabled by TearCare® Technology to Restasis¹ for the Treatment of Dry Eye (GlobeNewswire)
Jul-17-23 12:00PM	All You Need to Know About Sight Sciences, Inc. (SGHT) Rating Upgrade to Buy (Zacks) -6.03%
Jun-21-23 08:30AM	Cigna Expands Coverage of Glaucoma Surgical Procedures to Include Canaloplasty and Goniotomy (Trabeculotomy) (GlobeNewswire)
Jun-09-23 04:05PM	Sight Sciences Announces Addition of New Director Catherine Mazzacco (GlobeNewswire)
May-23-23 08:30AM	Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical System Technology (GlobeNewswire)
May-09-23 09:55AM	How Much Upside is Left in Sight Sciences, Inc. (SGHT)? Wall Street Analysts Think 38.78% (Zacks)
May-06-23 11:30AM	Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry (GlobeNewswire)
May-04-23 06:45PM	Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +6.27%
04:05PM	Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023 (GlobeNewswire)
May-01-23 04:05PM	Sight Sciences' Glaucoma and Dry Eye Technologies to be Featured in Multiple Clinical Presentations at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting (GlobeNewswire) +9.41%
Apr-26-23 04:05PM	Sight Sciences to Present at the Upcoming Bank of America Securities 2023 Health Care Conference (GlobeNewswire) +5.16%
Apr-20-23 04:05PM	Sight Sciences to Report First Quarter 2023 Financial Results on May 4, 2023 (GlobeNewswire)
Apr-19-23 01:57PM	Why Investors Shouldn't Be Surprised By Sight Sciences, Inc.'s (NASDAQ:SGHT) P/S (Simply Wall St.) +14.47%
04:05PM	Loading…
Apr-13-23 04:05PM	Sight Sciences to Host Surgical Glaucoma Investor Symposium on Friday, May 5, 2023 (GlobeNewswire) +6.31%
Apr-11-23 05:22AM	Strength Seen in Sight Sciences, Inc. (SGHT): Can Its 5.6% Jump Turn into More Strength? (Zacks)
Apr-03-23 04:05PM	Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer (GlobeNewswire)
Mar-30-23 08:00AM	Sight Sciences Defeats Invalidity Challenges Filed By Alcon and Ivantis In The U.S. Patent Office (GlobeNewswire)
Mar-23-23 11:25AM	Owning 30% shares,institutional owners seem interested in Sight Sciences, Inc. (NASDAQ:SGHT), (Simply Wall St.)
Mar-14-23 11:22AM	Sight Sciences, Inc. (NASDAQ:SGHT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-13-23 05:25PM	Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-09-23 08:30AM	Sight Sciences Launches the Ergo-Series of the OMNI® Surgical System (GlobeNewswire) -6.54%
Feb-23-23 04:05PM	Sight Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023 (GlobeNewswire)
Feb-22-23 04:05PM	Sight Sciences to Present at the Upcoming Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference (GlobeNewswire)
Feb-14-23 07:10AM	3 Prime Healthcare Takeover Targets (Motley Fool)
Jan-26-23 08:30AM	Sight Sciences Announces 1,000th TearCare® Customer Installation (GlobeNewswire)
Jan-09-23 04:20PM	Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
01:15PM	Sight Sciences (NASDAQ:SGHT) adds US$55m to market cap in the past 7 days, though investors from a year ago are still down 17% (Simply Wall St.)
Jan-04-23 10:00AM	Verana Health and Sight Sciences Collaborate on Glaucoma Research Using Curated Real-World Data from the IRIS Registry (PR Newswire)
Dec-29-22 09:10AM	Sight Sciences, Inc. (NASDAQ:SGHT) Q3 2022 Earnings Call Transcript (Insider Monkey)
Dec-13-22 01:09PM	Bullish Sight Sciences, Inc. (NASDAQ:SGHT) insiders filled their treasuries with US$4.6m worth of stock over last year (Simply Wall St.) +5.98%
Dec-08-22 08:30AM	Improvements in Signs and Symptoms of Dry Eye Disease From a Single TearCare® Treatment Sustained Through 12 Months (GlobeNewswire)
Nov-22-22 08:30AM	Sight Sciences to Present at the Upcoming Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-16-22 05:21AM	Sight Sciences Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS In Line (Simply Wall St.)
Nov-10-22 05:35PM	Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +19.26%
04:05PM	Sight Sciences Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-03-22 10:00AM	Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:30AM	Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI® Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure (GlobeNewswire)
Oct-20-22 05:20PM	Sight Sciences to Report Third Quarter 2022 Financial Results on November 10, 2022 (GlobeNewswire)
Oct-14-22 10:51AM	Institutional investors may adopt severe steps after Sight Sciences, Inc.'s (NASDAQ:SGHT) latest 12% drop adds to a year losses (Simply Wall St.)
Oct-04-22 03:38PM	Sight Sciences' Near-Term Upside Is Limited, Says This Analyst (Benzinga) +8.09%
Sep-29-22 08:30AM	Sight Sciences Announces Publication of Data Showcasing Superior Symptoms Improvements with the TearCare® System Compared to LipiFlow* in Patients with Advanced Dry Eye Disease (DED) (GlobeNewswire) -7.72%
Sep-28-22 08:30AM	Sight Sciences to Feature Interactive Panel Discussions of Real-World Use of the OMNI Surgical System as a Standalone (Non-Combination Cataract) Glaucoma Treatment at American Academy of Ophthalmology Annual Meeting (GlobeNewswire) +5.93%
Sep-16-22 08:00AM	Sight Sciences OMNI® Surgical System to Be Featured in Multiple Presentations at the 2022 European Society of Cataract and Refractive Surgery Annual Meeting (GlobeNewswire) -10.98%
Sep-13-22 03:01AM	Sight Sciences Announces Completion of Enrollment in SAHARA, a Randomized Clinical Trial of the TearCare® System vs Restasis® (GlobeNewswire)
Sep-02-22 08:00AM	Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-25-22 04:05PM	Sight Sciences to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase (GlobeNewswire)
Aug-23-22 08:03AM	Sight Sciences Introduces the SION Surgical Instrument The First Bladeless Device Used in Goniotomy (GlobeNewswire)
Aug-16-22 12:23PM	Sight Sciences Posts Long-Term Safety, Effectiveness Data For Glaucoma Surgical System (Benzinga)
08:01AM	Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI® Surgical System in Patients with Open Angle Glaucoma (GlobeNewswire)
Aug-12-22 02:31AM	Sight Sciences, Inc. (SGHT) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-11-22 04:05PM	Sight Sciences Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-10-22 10:25AM	Why Sight Sciences (SGHT) Might Surprise This Earnings Season (Zacks)
Aug-09-22 09:55AM	Wall Street Analysts Believe Sight Sciences, Inc. (SGHT) Could Rally 121%: Here's is How to Trade (Zacks)
Aug-04-22 10:00AM	Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Aug-02-22 09:55AM	Bears are Losing Control Over Sight Sciences, Inc. (SGHT), Here's Why It's a 'Buy' Now (Zacks)
Jul-29-22 08:48AM	Shareholders in Sight Sciences (NASDAQ:SGHT) have lost 73%, as stock drops 12% this past week (Simply Wall St.)
Jul-28-22 08:00AM	Sight Sciences to Report Second Quarter 2022 Financial Results on August 11, 2022 (GlobeNewswire)
Jul-19-22 04:26PM	Sight Sciences Announces the Appointment of Tamara Fountain, M.D. to its Board of Directors (GlobeNewswire) +9.37%
Jul-18-22 09:55AM	Wall Street Analysts See a 200% Upside in Sight Sciences, Inc. (SGHT): Can the Stock Really Move This High? (Zacks)
Jul-06-22 01:55PM	Sight Sciences, Inc. (NASDAQ:SGHT) is up 20%, while insiders who purchased US$4.8m are up 30% (Simply Wall St.)
May-31-22 08:00AM	Sight Sciences OMNI® Surgical System Reduces IOP, Daily Fluctuations in IOP and Medication Use, as Shown in Newly Published 12-Month Clinical Data (GlobeNewswire)
May-19-22 08:00AM	Sight Sciences to Present at the Upcoming Piper Sandler Virtual Ophthalmology & Diabetes Symposium (GlobeNewswire) -8.65%
May-10-22 04:05PM	Sight Sciences Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-07-22 10:40AM	What You Need To Know About Sight Sciences, Inc.'s (NASDAQ:SGHT) Investor Composition (Simply Wall St.)
Apr-29-22 08:00AM	Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference (GlobeNewswire)
Apr-20-22 04:05PM	Sight Sciences Announces Multiple Presentations and Event at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting (GlobeNewswire) -5.22%
Apr-14-22 04:05PM	Sight Sciences to Report First Quarter 2022 Financial Results on May 10, 2022 (GlobeNewswire) -5.23%
Mar-26-22 02:31PM	Earnings Release: Here's Why Analysts Cut Their Sight Sciences, Inc. (NASDAQ:SGHT) Price Target To US$28.33 (Simply Wall St.)
Mar-25-22 07:08AM	Sight Sciences' Q4 Earnings, FY22 Guidance Beat Street View (Benzinga) -8.78%
12:00AM	Sight Sciences, Inc. (SGHT) Q4 2021 Earnings Call Transcript (Motley Fool)
Mar-24-22 04:05PM	Sight Sciences Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
04:04PM	Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI® Surgical System in Pseudophakic Eyes with Open-Angle Glaucoma (GlobeNewswire)
Mar-16-22 08:00AM	Sight Sciences Announces Appointment of Brenda Becker to Board of Directors (GlobeNewswire) +5.68%
Mar-03-22 04:05PM	Sight Sciences to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022 (GlobeNewswire)
Mar-02-22 08:00AM	Sight Sciences Announces Multiple Presentations at the 2022 American Glaucoma Society Annual Meeting (GlobeNewswire)
Feb-28-22 07:53AM	3 Medical Device Stocks Poised to Beat This Earnings Season (Zacks)
Feb-21-22 04:05PM	Sight Sciences to Participate in the Upcoming Citi Virtual Healthcare Conference (GlobeNewswire)
10:37AM	Fulgent Genetics (FLGT) to Post Q4 Earnings: What's in Store? (Zacks)
Feb-18-22 11:41AM	Medtronic (MDT) to Report Q3 Earnings: What's in Store? (Zacks)
Feb-17-22 08:00AM	Sight Sciences Launches Dont Wait for Too Late Awareness Campaign for Glaucoma (GlobeNewswire) -6.42%
Feb-08-22 08:34AM	Why Earnings Season Could Be Great for Sight Sciences (SGHT) (Zacks) +8.36%
Jan-13-22 08:54AM	Insiders who bought Sight Sciences, Inc. (NASDAQ:SGHT) stock in the last 12 months recover some losses, but still down US$12k (Simply Wall St.)

Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Encrantz Staffan	Director	Nov 30	Buy	3.46	140,777	486,638	1,012,150	Dec 01 07:39 PM
Encrantz Staffan	Director	Nov 29	Buy	3.50	3,223	11,280	871,373	Dec 01 07:39 PM
Encrantz Staffan	Director	Nov 28	Buy	3.46	253,669	877,137	868,150	Nov 28 08:32 PM
Encrantz Staffan	Director	Nov 27	Buy	3.31	246,331	815,947	614,481	Nov 28 08:32 PM
Badawi David	Chief Technology Officer	Nov 24	Option Exercise	0.11	150,000	16,500	1,631,196	Nov 28 08:16 PM
Encrantz Staffan	Director	Nov 24	Buy	3.09	21,855	67,427	368,150	Nov 28 08:32 PM
Encrantz Staffan	Director	Nov 22	Buy	2.50	41,085	102,708	346,295	Nov 22 06:19 PM
Encrantz Staffan	Director	Nov 21	Buy	2.48	68,477	169,535	305,210	Nov 22 06:19 PM
Encrantz Staffan	Director	Nov 20	Buy	2.25	79,234	178,189	236,733	Nov 22 06:19 PM
Encrantz Staffan	Director	Nov 17	Buy	2.19	126,664	277,293	157,499	Nov 20 09:45 PM
Encrantz Staffan	Director	Nov 16	Buy	2.00	339	678	30,835	Nov 20 09:45 PM
Encrantz Staffan	Director	Nov 14	Buy	2.00	3,462	6,914	30,496	Nov 16 05:44 PM
Park Sam Boong	Chief Operating Officer	Sep 14	Option Exercise	1.96	37,668	73,829	89,092	Sep 15 06:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SGHT

Sight Sciences Inc

Upgrade your FINVIZ experience